Dr. Ai-Ja Jackson

Yes, I do want to piggyback off of what Dr. Takolis Hassan said and just say thank you for having me on the show.

With regard to GLP-1s, I do think they are more so of a quick start.

But if you don't address the underlying causes of, you know, eating habits, exercising habits, moving daily, like she mentioned, once you kind of complete that medication, you

are likely to rebound because if you haven't changed those habits prior to or while you're on the medication you're not going to change them once you stop so let me ask you is it a fad drug are you as pharmacists are you concerned that this is a fad

Me personally, I am a little bit concerned that it's a fad because I've seen patients that actually need the medication for a diabetic diagnosis and they aren't able to get the medication because it's either out of stock, low inventory, things like that.

I think once you have one person, be it celebrity, someone you know that has taken a GLP-1, lost all this weight, people are going to their providers and saying, hey, my so-and-so is on this.

I want to get on it too to lose the weight.

So I do think it's a fad.

I wish there was more education from providers, from pharmacists, just about that.

the GLP ones in general, to really give patients and people, whether they'll listen or not, really good insight on what they're getting themselves into.

Yeah, so actually DLP-1s are one of the medications that we are looking up to adding to our program.

The program that I'm building is fairly new, but basically pharmacogenomics looks at the study of how your body metabolizes or breaks down certain medications depending on the pathway.

So depending on how fast or slow of a metabolizer you are, that can be an indication of if this medication will work for you or not.

A lot of the information for pharmacogenomics is informational, but it gives you good insight on, okay, if I take this medicine,

If I am, for example, a poor metabolizer is one of the categories.

If I'm a poor metabolizer, I know this medication is going to stay in my body a lot longer than someone that's a normal metabolizer, increasing my risk of side effects.

With GLP-1s, it's still kind of something that's new, but it's a good indication of, okay, you know, if a patient is taking this GLP-1, what kind of metabolizer are they and what effect will that have on them either having success or adverse events, not having success at all on this medication?

Because this is right up my alley right there.

Yeah.

So I've worked on the PBM, which is a pharmacy benefit manager side of pharmacy.